



## **PMV Pharmaceuticals Announces Participation at the Cowen 41st Annual Health Care Conference**

February 23, 2021

CRANBURY, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., President & Chief Executive Officer, will participate in the Lung Cancer Panel at the Cowen 41<sup>st</sup> Annual Health Care Conference taking place virtually on March 1-4, 2021. The company will also participate in one-on-one investor meetings at the conference.

Panel details:

Cowen 41<sup>st</sup> Annual Health Care Conference Lung Cancer Panel

Date: Tuesday, March 2, 2021

Time: 11:10am

### **About PMV Pharma**

PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. PMV Pharma is headquartered in Cranbury, New Jersey. For more information, please visit [www.pmvpharma.com](http://www.pmvpharma.com).

Contact

For Investors and Media:

Winston Kung  
Chief Financial Officer  
[investors@pmvpharma.com](mailto:investors@pmvpharma.com)

Source: PMV Pharmaceuticals, Inc.



Source: PMV Pharmaceuticals, Inc.